
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
The Oncology Institute Inc (TOIIW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TOIIW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -34.01% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.16 | 52 Weeks Range 0.01 - 0.20 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.20 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -602.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.96% | Operating Margin (TTM) -9.49% |
Management Effectiveness
Return on Assets (TTM) -17.66% | Return on Equity (TTM) -277.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 66946108 |
Shares Outstanding - | Shares Floating 66946108 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
The Oncology Institute Inc
Company Overview
History and Background
The Oncology Institute, Inc. (TOI) was founded to deliver value-based community cancer care and is committed to helping make cancer care more accessible and affordable to patients.
Core Business Areas
- Comprehensive Cancer Care: TOI operates a network of community-based cancer centers, providing a full range of cancer care services, including medical oncology, radiation oncology, and hematology.
- Value-Based Care Programs: TOI focuses on value-based care models, aiming to improve patient outcomes and reduce healthcare costs.
- Clinical Trials: TOI participates in clinical trials, offering patients access to cutting-edge treatments and research.
Leadership and Structure
The leadership team includes key executives focused on clinical operations, finance, and business development. The organizational structure consists of a corporate headquarters supporting a network of community-based clinics.
Top Products and Market Share
Key Offerings
- Medical Oncology Services: Chemotherapy, immunotherapy, targeted therapy, and other systemic treatments. Limited market share data available specifically for TOI. Competitors include large hospital systems and other oncology groups.
- Radiation Oncology Services: Radiation therapy for various cancer types. Limited market share data available specifically for TOI. Competitors include large hospital systems and other oncology groups.
- Hematology Services: Treatment of blood disorders and cancers. Limited market share data available specifically for TOI. Competitors include large hospital systems and other hematology groups.
Market Dynamics
Industry Overview
The oncology market is growing due to an aging population and advancements in cancer treatment. It is highly competitive and evolving towards value-based care models.
Positioning
TOI positions itself as a provider of comprehensive, value-based cancer care in community settings, aiming to improve accessibility and affordability.
Total Addressable Market (TAM)
The global oncology market is estimated at hundreds of billions of dollars. TOI's position allows it to capture a segment of this market focused on community-based and value-based care.
Upturn SWOT Analysis
Strengths
- Value-based care model
- Community-based clinics
- Comprehensive service offerings
- Participation in clinical trials
Weaknesses
- Limited brand recognition compared to larger hospital systems
- Reliance on reimbursement rates
- Smaller scale compared to national oncology providers
- High debt
Opportunities
- Expansion into new geographic markets
- Increased adoption of value-based care models
- Partnerships with payers and healthcare systems
- Technological advancements in cancer treatment
Threats
- Changes in reimbursement policies
- Increased competition from larger healthcare providers
- Rising operating costs
- Drug pricing pressures
Competitors and Market Share
Key Competitors
- USON
- CRGV
- HCA
Competitive Landscape
TOI faces competition from larger hospital systems and national oncology providers. Its advantage lies in its community-based model and value-based care approach. Disadvantages include smaller scale and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth can be determined by analyzing past revenue and patient volume trends from financial reports.
Future Projections: Future growth projections can be found in analyst reports and company presentations, focusing on revenue growth, clinic expansion, and patient volume.
Recent Initiatives: Recent initiatives would be related to clinic expansion, partnerships, and the development of value-based care programs.
Summary
The Oncology Institute operates under a value-based care model focused on community-based cancer care. While its unique approach offers potential, the company faces stiff competition from larger healthcare providers and relies heavily on reimbursement rates. Its small scale and high debt remain challenges. The company should focus on expanding its network, securing partnerships, and carefully managing expenses to improve its financial stability and market position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About The Oncology Institute Inc
Exchange NASDAQ | Headquaters Cerritos, CA, United States | ||
IPO Launch date 2020-06-04 | CEO & Executive Director Dr. Daniel Virnich FACHE, M.B.A., M.D. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 825 | Website https://theoncologyinstitute.com |
Full time employees 825 | Website https://theoncologyinstitute.com |
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.